9th October, 2024, Mumbai: Alembic Pharmaceuticals today announced that it has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) located at Panelav.
The inspection was successfully completed without any Form 483 observation. The inspection was conducted from 7th October, 2024 to 8th October, 2024.
No responses yet